Fusion Antibodies Stock
Fusion Antibodies plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Adrian Robert Kinkaid
- Employees
- 27
- Market cap
- £8 M
- IPO
- 18/12/2017
Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United…
Fusion Antibodies stock: price history
1D
+6.6%
1W
-35.5%
1M
-42.7%
6M
-55.5%
YTD
-53.9%
1Y
-55.5%
2Y
+31.6%
5Y
-94.9%
10Y
–
Next earnings date
Next earnings date
07/12/2026 (in 51 days)
Volatility around earnings
~1% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 15/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Fusion Antibodies
Fusion Antibodies stock metrics
P/E
-6.52
P/B
4.69
EV/EBITDA
-4.89
RETURN ON EQUITY
-39.3%
NET MARGIN
-50.1%
DEBT/EQUITY
0.2
DIVIDEND YIELD
0.0%
AS OF
31/03/2026
Free float & liquidity
FREE FLOAT
87.9%
FLOAT SHARES
110,053,009
AVG. DAILY VOLUME (30D)
674,939
Comparable stocks
Frequently asked questions about Fusion Antibodies stock
What does Fusion Antibodies do?
Fusion Antibodies plc is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Adrian Robert Kinkaid, the company employs around 27 people.
The IPO was on 18/12/2017; the stock trades on LSE under the ticker FAB.L.
When does Fusion Antibodies report next?
The next earnings date is 07/12/2026.
Around past earnings, price swings were roughly 1% stronger than usual.
Does Fusion Antibodies pay a dividend?
No, Fusion Antibodies currently does not pay a dividend.
Which stocks are comparable to Fusion Antibodies?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Fusion Antibodies stock analyzed?
Clicking "Analyze stock" lets five strategies assess Fusion Antibodies against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.